Shelter Pharma Limited has announced its unaudited financial results for the half year ended September 30, 2025, showcasing a mixed performance compared to the previous year. The pharmaceutical manufacturer reported a profit before tax of Rs 601.45 crore, down from Rs 967.70 crore in the corresponding period last year.

Financial Highlights

Despite the decrease in revenue and profit before tax, the company's basic earnings per share (EPS) improved to Rs 3.89, up from Rs 3.06 in the previous year, indicating a 27.1% increase.

Balance Sheet Strengthens

Shelter Pharma's balance sheet showed signs of growth:

• Total assets increased to Rs 6,689.54 crore as of September 30, 2025, up from Rs 4,833.55 crore on March 31, 2025.
• Reserves and surplus grew to Rs 3,561.47 crore from Rs 3,116.08 crore.
• The company received Rs 1,350.84 crore as money against share warrants.

Operational Performance

The cost of material consumed stood at Rs 2,490.11 crore for the half-year period. Employee benefit expenses were reported at Rs 85.40 crore, while other expenses amounted to Rs 120.72 crore.

Cash Flow and Liquidity

The company's cash and cash equivalents at the end of the period stood at Rs 527.96 crore, showing a significant increase from Rs 341.99 crore at the beginning of the year. This improvement in liquidity may provide the company with more flexibility for future investments and operations.

Corporate Governance

The Board of Directors approved these results in a meeting held on November 10, 2025. The company reported no investor complaints during the review period, reflecting positively on its investor relations practices.

Utilization of Funds

According to the auditor's report, Shelter Pharma has fully utilized the Rs 930.35 crore raised through a preferential issue of convertible warrants into equity shares for working capital requirements, with no deviation from the stated objectives.

Shelter Pharma continues to operate in the pharmaceutical manufacturing sector, facing challenges in revenue growth but maintaining profitability and strengthening its balance sheet.

Shelter Pharma Limited , a pharmaceutical and nutraceutical company, has announced securing another international order from Taha Drugs & Chemicals Co. Ltd, a Sudan-based entity. The latest order is worth ₹27,540 for D3 Cure Capsules, adding to the company's growing international business portfolio.

Latest Order Details

The recent order announcement provides the following specifications:

Previous Order History

This marks the third order from the same Sudan-based client, demonstrating a continued business relationship with the international partner. The company has previously secured orders including one worth ₹98,875 for Joemega Capsules and Vitamin Tablets, and another worth ₹27,600 for Joemega Capsules.

Regulatory Compliance

Shelter Pharma Limited has confirmed that this latest order does not constitute a related party transaction. The company's promoters have no interest in Taha Drugs & Chemicals Co. Ltd, ensuring transparency in operations and compliance with regulatory requirements under SEBI regulations.

Company Profile

Shelter Pharma Limited positions itself as a leading pharmaceutical and nutraceutical company dedicated to research, innovation, and quality healthcare solutions. The company operates state-of-the-art facilities and maintains a commitment to ethical practices, focusing on producing safe and effective products that enhance quality of life globally.

These consecutive orders from the Sudan-based partner indicate strengthening international relationships and demonstrate the company's ability to secure diverse product orders across different therapeutic segments, which may contribute positively to the company's financial performance.